DIAGNOSIS, PROGNOSIS, AND TREATMENT OF KIDNEY DISEASE

WIPO Patent Application WO/2013/010085

A3

The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.

BERG ANDERS H (US)
KARUMANCHI S ANANTH (US)
THADHANI RAVI I (US)

PCT/US2012/046684

April 11, 2013

July 13, 2012

Click for automatic bibliography generation  

BETH ISRAEL HOSPITAL (US)
BERG ANDERS H (US)
KARUMANCHI S ANANTH (US)
THADHANI RAVI I (US)

C07K16/00; G01N33/566

US20110104818A1

2011-05-05

BALION ET AL.: "Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients", KIDNEY INTERNATIONAL, vol. 53, 1998, pages 488 - 495
COCA ET AL.: "Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review", KIDNEY INTERNATIONAL, vol. 73, 19 December 2007 (2007-12-19), pages 1008 - 1016

BIEKER-BRADY, Kristina et al. (101 Federal Street15th Floo, Boston MA, US)

View/Download PDF      PDF Help

Previous Patent: CLAMP CIRCUMFERENCE MEASURING GAUGE

Next Patent: PATIENT/INVALID HANDLING SUPPORT